SEATTLE, Wash and VANCOUVER, British Columbia, March 14, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced fourth quarter and year-end 2018 financial results. Recent Highlights Completion of…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, March 5, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its fourth quarter and year-end 2018 financial results on Thursday, March 14, 2019. Company management will host…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, Feb. 22, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced final data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) clinical study of cytisinicline in smokers. Study results will be…
/Read More
Topline data from ORCA-1 trial expected in mid-2019 SEATTLE, Wash. and VANCOUVER, British Columbia, Feb. 20, 2019 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is…
/Read More
SEATTLE, Wash. and VANCOUVER, British Columbia, Dec. 18, 2018 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided a clinical development update. The U.S. Food and Drug Administration (FDA) has confirmed that they are in agreement with Achieve’s Initial…
/Read More